ALSUntangled #80: ISRIB (Integrated stress response InhiBitor)

Area of Science:

• Neuroscience
• Molecular Biology
• Drug Discovery

Background:

• Amyotrophic lateral sclerosis (ALS) involves an overactive integrated stress response (ISR).
• The ISR contributes to stress granule formation, potentially triggering cell death in ALS.
• ISRIB is a molecule investigated for its ability to attenuate the ISR.

Purpose of the Study:

• To review the potential of ISRIB as an alternative treatment for ALS.
• To assess the current evidence regarding ISRIB's efficacy and safety in ALS.

Main Methods:

• Review of pre-clinical data in ALS cell models.
• Analysis of anecdotal patient reports on symptomatic improvements.
• Evaluation of existing literature on ISRIB's mechanism of action.

Main Results:

• Pre-clinical studies suggest ISRIB is beneficial in ALS cell models.
• Anecdotal reports indicate symptomatic improvements with minimal side effects in some patients.
• Significant questions remain regarding ISRIB's solubility, bioavailability, and lack of clinical trials.

Conclusions:

• ISRIB shows promise in pre-clinical ALS models by modulating the ISR.
• Insufficient clinical evidence and safety data currently prevent endorsement of ISRIB for ALS treatment.
• Further research, including clinical trials, is essential to determine ISRIB's safety and efficacy in ALS patients.